NR4A1 and carcinoma: For comparison, a two-year treatment with the medication Abemaciclib in patients with hormone receptor-positive high-risk early-stage carcinoma results in a relative risk reduction of 35% in terms of invasive recurrence or distant metastasis - which is generally considered a clinically significant effect.